Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pharma firms in RNAi deals

July 17, 2006 | A version of this story appeared in Volume 84, Issue 29

Alnylam and Merck have consolidated their two existing RNA interference pacts into one collaboration that will focus on nine therapeutic targets to be selected by Merck. Under the revised agreement, Merck will participate at an earlier stage in the R&D of those RNAi therapeutics. Alnylam can choose three of the nine programs for Merck to cofund and will have the right to copromote those drugs in the U.S. Among the candidates explored in the earlier pact, the companies will continue to advance a spinal cord injury therapy, but they will not jointly develop a product for age-related macular degeneration. Separately, Abbott Laboratories is collaborating with Fisher Biosciences' Dharmacon unit to develop therapeutics based on short interfering RNA initially for oncology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.